The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lercanidipine Mylan 20mg film-coated tablets

20 milligram(s) Film-coated tablet

McDermott Laboratories Ltd t/a Gerard LaboratoriesPA0577/155/002

Main Information

Trade NameLercanidipine Mylan 20mg film-coated tablets
Active SubstancesLercanidipine hydrochloride
Strength20 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderMcDermott Laboratories Ltd t/a Gerard Laboratories
Licence NumberPA0577/155/002

Group Information

ATC CodeC08CA Dihydropyridine derivatives
C08CA13 lercanidipine

Status

Authorised/WithdrawnAuthorised
Licence Issued03/06/2011
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0020-003-003
Interchangeable List DocumentPDF of Interchangeable List
« Back